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Case Report
A fatal case of gram negative bacterial sepsis associated with disseminated
strongyloidiasis in an immunocompromised patient 
Naima Fasih, Seema Irfan, Usman Sheikh, M. Asim Beg
Department of Pathology and Microbiology , Aga Khan University Hospital, Karachi.
Abstract
We report a fatal case of disseminated strongyloidiasis
in a patient with multiple myeloma receiving chemotherapy.
A fifty-seven years old man presented with severe diarrhoea
and vomiting, fever, weight loss and dysphagia due to mouth
ulcers. Despite broad-spectrum intravenous antibiotics,
albendazole (anti protozoal) and supportive treatment, the
patient died of Gram-negative sepsis. 
Introduction
Strongyloides stercolaris (S. stercoralis) is an
intestinal nematode of humans. It has a worldwide
geographical distribution but is endemic in the tropics and
the subtropical regions of the world. It is estimated that tens
of millions of persons are infected worldwide, although no
precise estimate is available.1 Although most infected
individuals are asymptomatic, S. stercoralis is capable of
transforming into a fulminant fatal illness under certain
conditions that are associated with an immunocompromised
host such as patients on steroid therapy, those infected with
human T cell lymphotropic virus-1 (HTLV-1) and Human
immunodeficiency virus (HIV).2,3 The hyperinfective state
is associated with massive invasion of the gastrointestinal
and respiratory systems and may result in widespread
dissemination into other body organs or invasive
strongyloidiasis.4
Case Report 
A fifty-seven years old male, diagnosed with
multiple myeloma and on chemotherapy for thirteen days,
came to the Aga Khan University Hospital with
complaints of fever, loose watery diarrhoea, progressive
weight loss and dysphagia due to mouth ulcers. On
examination his vitals were stable and his systemic
examination was unremarkable except that he was pale
and mildly icteric. Routine investigations including blood
complete picture, stool and urine routine examination,
urine culture, liver and renal profiles were done.
Haemoglobin was found to be 12.6 g/dl and total
leukocyte count was 1.5 x109/l with 0.7% eosinophils .His
liver and renal profiles were deranged with total bilirubin
2.7, gamma glutamine transferase 193 I.U/L, alanine
transferase 193 I.U/L, blood urea nitrogen 45 mg/dl and
creatinine 2 mg/dl. Routine stool and urine examination
were normal with no microorganism grown in urine
culture. The patient was admitted to the oncology section.
Next day, he developed rectal bleeding and endoscopy
showed multiple ulcerations. He was put on full
supportive care and broad-spectrum antibiotics were
prescribed but in spite of all efforts his condition
continued to deteriorate. Two routine stool examinations
were done, the first sent on day 8 of admission was
unremarkable, however the second one sent on day 12 of
admission revealed S. stercoralis larvae. Patient was
immediately given antiprotozoal albendazole. Blood
cultures on day 8 of admission showed E. coli. In spite of
all supportive measures and broad-spectrum intravenous
antibiotics and antiprotozoal medications, the patient died
of sepsis after fourteen days of hospitalization.
Discussion
Our patient had multiple myeloma and was given
appropriate chemotherapy including dexamethasone.
Although clinical syndromes of S. stercoralis encompass a
range from acute and chronic strongyloidiasis to
hyperinfection and disseminated infection, hyperinfection
results when host immunity is impaired especially by
corticosteroid therapy and less commonly other
immunosuppressive drugs, haematological malignancies,
malnutrition or Infection with HTLV-15 or HIV. 
The life cycle of S. stercoralis is complex. The usual
route of infection in humans is through skin contact with
soil contaminated with infective filariform larvae. Humans
can also be infected via the lower gastrointestinal tract or
perianal region from larvae that transform into infective
stage during their passage in faeces. This "autoinfection"
cycle explains the massive larval invasion seen in
Strongyloides hyperinfection syndrome. The larvae pass via
the bloodstream to the lungs, break into the alveolar spaces,
ascend to the glottis are then swallowed and go to their final
habitat in the small intestine. Deposition of eggs begins
about four weeks after the initial infection. Our patient died
of gram-negative bacteria sepsis. Gram-negative bacteria
and other bowel flora may gain access to the blood stream
through ulcers in the bowel or by transport on the surface or
in the gut of migrating larvae. Bacterial sepsis, meningitis,
and pneumonia occur frequently. The mortality associated
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with untreated disseminated strongyloidiasis approaches
100%, and even with treatment it exceeds 25%. There are
many case reports presents that demonstrate fatal outcome,
Reddy et al6 described two fatal cases of disseminated
S.stercolaris one with pemphigus vulgaris and other with
non Hodgkin lymphoma and both on steroid therapy.
Hauber et al7 reported fatal outcome of hyperinfection
syndrome despite successful eradication of S.stercolaris
with  subcutaneous ivermectin. Treatment goal in
strongyloidiasis is prevention of hyperinfection so total
eradication of parasite is required as single viable worm is
able io elicit hyperinfection in right circumstances.
Treatment options available are azole group including
Thiabendazole 25 mg/kg twice daily for three days,
Albendazole 400mg twice daily for three days or
Mebendazole.  Ivermectin is better tolerated and became the
drug of choice as compared to thiabendazole. Broad
spectrum antibiotics should be used for gram negative
sepsis in hyperinfection syndrome. In hyperinfection
syndrome early diagnosis and treatment may be life saving.1
So any individual with risk factors for acquiring S.
stercoralis infection should be screened. Relying on stool
studies alone for screening is inadequate, as supported by
reports of hyperinfection developing in persons with
negative screening stool exams. A single stool examination
is said to be about 50% sensitive for diagnosing S.
stercoralis infection in someone with symptomatic chronic
disease.8 In the asymptomatic individual, stool examination
is probably even less sensitive.1 To increase sensitivity of
stool examination, faeces samples of these patients are
processed and analyzed according to the following
methods: Lutz, formalin ethyl acetate, Baermann, Harada-
Mori and agar plate culture, in which agar plate culture had
sensitivity of 68-70%.9 Methods to sample duodenal fluid
are more invasive and therefore less desirable.1 Because of
higher sensitivity, the diagnosis is often made by serological
tests, such as the enzyme-linked immunoassay offered by
Center of Disease Control and Prevention
(CDC.Atlanta.USA.) that has sensitivity of 95%.Yori et al10
conducted a stool and serosurvey for S. stercoralis in a
community in the Peruvian Amazon region. S. stercoralis
was identified in the stool of 69 (8.7%) of 792 participants.
Six hundred nine sera were tested using by an enzyme-
linked immunosorbent assay (ELISA), which had a
sensitivity of 92% and a specificity of 94%.10
Conclusion
Early diagnosis of disseminated Strogyloides
infection and prompt therapy have a marked impact on
disease outcome. Screening using enzyme-linked
immunosorbent assay (ELISA) should be considered
mandatory for patients who have a history of travel or
residence in a disease-endemic area especially with risk
factors for disseminated disease (e.g., corticosteroid use and
human T-lymphotropic virus type I infection). Stool
microscopy using repeated stool samples should be used as
a screening alternative in settings where serodiagnosis
facility is not available. 
Hyperinfection Strogyloides syndrome should be
suspected in immunocompromised patients that develop
severe generalized abdominal pain, ileus, diffuse pulmonary
infiltrates, shock, meningitis or sepsis from gram negative
bacilli.
Early diagnosis and prompt treatment are necessary
if fatalities have to be avoided.
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